Fairvalue-Calculator Fairvalue-Calculator

Beijing Hotgen Biotech Co (688068) Fair Value & Analysis

Healthcare · CN · Market cap 7.5B CNY

Price¥80.40
Fair Value¥142.13
Upside+76.8%
Quality80/100
Evidence: Low Range ¥106.59 – ¥177.66

Analysis

Beijing Hotgen Biotech Co (688068) currently trades at ¥80.40, while our model-based Fair Value estimate is ¥142.13 — implying the stock looks roughly 76.8% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, including upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -63% Samsung Biologics Co (207940) +1%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.